As gene ther­a­py ri­vals ad­vance, Bio­gen moves clos­er to spin­ning out he­mo­phil­ia drugs, R&D

Lest any­one for­get, Bio­gen is fo­cused pri­mar­i­ly on neu­ro­science. And it’s mov­ing at a steady clip to spin off its he­mo­phil­ia busi­ness in a tac­tic de­signed to un­der­score that strat­e­gy. Bio­gen to­day says the busi­ness will launch as Biover­a­tiv in ear­ly 2017 and trade as $BIVV.

The busi­ness at Biover­a­tiv will start by fo­cus­ing on con­tin­u­ing to com­mer­cial­ize Eloc­tate and Al­pro­lix, which were de­vel­oped in part­ner­ship with Stock­holm-based So­bi. And there’s a pipeline of new projects look­ing at ex­pand­ing their use while adding new ef­forts on gene ther­a­pies and more for he­mo­phil­ia A and B.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN